ROPINIROLE HYDROCHLORIDE by Novartis is non-ergoline dopamine agonist. Approved for parkinson’s disease (pd), moderate-to-severe primary restless legs syndrome (rls), parkinson's disease. First approved in 2012.
Drug data last refreshed 18h ago
non-ergoline dopamine agonist. The precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, although it is thought to be related to its ability to stimulate dopamine D 2 receptors within the caudate-putamen in the brain. The precise mechanism of action of…
Worked on ROPINIROLE HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study